Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
ETNB Stock Chart & Stats
$14.79
$0.27(4.28%)
At close: 4:00 PM EST
$14.79
$0.27(4.28%)
Day’s Range― - ―
52-Week Range$4.16 - $15.06
Previous Close$6.59
Volume1.55M
Average Volume (3M)7.60M
Market Cap
$2.19B
Enterprise Value$1.03B
Total Cash (Recent Filing)$561.16M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 06, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding148,308,240
10 Day Avg. Volume2,532,364
30 Day Avg. Volume7,604,926
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.04
Price to Sales (P/S)0.00
P/FCF Ratio-2.23
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue48.90K
Enterprise Value/Gross Profit-57.05K
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$26.64Price Target Upside80.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Acquisition Premium89bio announced that it has entered into a merger agreement to be acquired by Roche at a price of $14.50 per share in cash at closing, representing a premium of approximately 79% to ETNB's closing stock price on September 17.
Market PotentialHigh conviction in the MASH space as a large and growing market with the FGF21 class being one of the most potent anti-fibrotic mechanisms in development.
Strategic FitThis transaction reflects pegozafermin's potential best-in-disease profile for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis and highlights its strategic fit within Roche's cardiovascular, renal, and metabolism portfolio.
Bears Say
89bio News
ETNB FAQ
What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $4.16 and its highest was $15.06 in the past 12 months.
What is 89bio’s market cap?
89bio’s market cap is $2.19B.
When is 89bio’s upcoming earnings report date?
89bio’s upcoming earnings report date is Nov 06, 2025 which is in 10 days.
How were 89bio’s earnings last quarter?
89bio released its earnings results on Aug 07, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.501 by -$0.209.
Is 89bio overvalued?
According to Wall Street analysts 89bio’s price is currently Undervalued.
Does 89bio pay dividends?
89bio does not currently pay dividends.
What is 89bio’s EPS estimate?
89bio’s EPS estimate is -0.51.
How many shares outstanding does 89bio have?
89bio has 148,308,240 shares outstanding.
What happened to 89bio’s price movement after its last earnings report?
89bio reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.501. Following the earnings report the stock price went up 1.552%.
Which hedge fund is a major shareholder of 89bio?
Currently, no hedge funds are holding shares in ETNB
89bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.64 (80.12% Upside)
$26.64 (80.12% Upside)
Blogger Sentiment
Bullish
ETNB Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 501.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.34%
12-Months-Change
Fundamentals
Return on Equity
-86.86%
Trailing 12-Months
Asset Growth
3.67%
Trailing 12-Months
Company Description
89bio
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
ETNB Stock 12 Month Forecast
Average Price Target
$26.64
▲(80.12% Upside)
Technical Analysis
Travere Therapeutics
―
Immunovant
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Dyne Therapeutics
―
Ownership Overview
14.71% Insiders
14.68% Mutual Funds
0.33% Other Institutional Investors
51.09% Public Companies and Individual Investors